Shilajit Evidence Scorecard: Why the Trial Base Doesn't Match the Hype
Shilajit is searched more than 100,000 times a month in India alone. The published clinical trial base behind it would not fill a single page of a research notebook. That gap — between cultural reach and evidentiary depth — is the most important thing a reader of this herb can know.
The verdict in 30 seconds
My HerbVerdict rating is LIMITED. As of April 2026, only six PubMed-indexed RCTs with sample size ≥ 30 have been published on Shilajit in humans. They cluster around testosterone in healthy men and exercise-related fatigue. The evidence does not support most of the broader benefits Indian retail marketing claims for the herb. Heavy-metal contamination in unpurified product remains the most concrete consumer concern.
What is Shilajit?
Shilajit is a tar-like exudate that seeps from cracks in Himalayan and Hindu Kush rocks during the warm months. It is technically not a herb — it is a phyto-mineral, a partly decomposed plant matter that has been mineralised over centuries.
The Sanskrit name translates loosely as "destroyer of weakness." Charaka Samhita lists Shilajit as a rasayana — a rejuvenative — used for general weakness, urinary disorders, and as a tonic. That is traditional context. It is not a clinical claim.
The bioactive markers most labs measure are fulvic acid (15–20% by weight in genuine purified resin), humic substances, and dibenzo-α-pyrones. The fulvic acid fraction is what most modern Shilajit research has tried to characterise.
What the research actually shows
I searched PubMed in April 2026 for `shilajit AND human` filtered to clinical-trial designs. Only six RCTs with sample size of at least 30 met the bar. I'm reporting them all — the positive ones and the limited ones.
Outcome 1 — Testosterone and reproductive markers in men
Pandit et al., 2016 — PrimaVie purified Shilajit
| Journal | Andrologia |
|---|---|
| Design | Double-blind, placebo-controlled RCT in healthy men 45–55 |
| Dose | 250 mg twice daily of purified Shilajit (PrimaVie, Natreon) |
| Key finding | Significant increases in total and free testosterone, plus DHEA-S, vs placebo at day 90. |
| Limitation | Single-centre. Industry-funded (Natreon makes PrimaVie). Healthy men only — does not generalise to clinical hypogonadism. |
| Source | PubMed 26395129 |
Biswas et al., 2010 — Spermatogenic activity in oligospermia
| Journal | Andrologia |
|---|---|
| Design | Single-arm intervention study in men with oligospermia |
| Key finding | Improvements in sperm count, motility, and serum testosterone reported at 90 days. |
| Limitation | No placebo arm. Selection bias — only men with diagnosed oligospermia. Cannot attribute effect to Shilajit alone. |
| Source | PubMed 19696985 |
Outcome 2 — Exercise fatigue and connective tissue
Keller et al., 2019 — Strength preservation
| Journal | Journal of the International Society of Sports Nutrition |
|---|---|
| Dose | 250 or 500 mg/day Shilajit, 8 weeks, with resistance training |
| Key finding | Higher-dose group preserved muscular strength after a fatiguing protocol significantly better than placebo. |
| Limitation | Healthy men only. Surrogate biomarker outcomes; clinical translation debated. |
| Source | PubMed 30728074 |
Outcome 3 — Cognition (preliminary signal only)
A 2012 review in International Journal of Alzheimer's Disease discussed Shilajit's potential procognitive activity based on in-vitro and animal evidence. As of April 2026, no large human RCT for cognitive outcomes has been published.
Evidence verdict
Why "Limited" rather than "Promising"
Two narrow signals — testosterone in healthy aging men and fatigue-related strength preservation — replicated at one or two centres each, almost entirely industry-funded, in narrow demographics, is not a Promising evidence base on the HerbVerdict scale. Combined with the well-documented purity and heavy-metal risks in the Indian retail market, the consumer-protection question matters more than the efficacy debate at this point.
Dosage as used in the trials (not a recommendation)
Across the trials I reviewed: - 250–500 mg/day of purified Shilajit extract for 8–12 weeks was the most common dose - Most trials used PrimaVie (a branded extract from Natreon) or similar standardised preparations - Resin form was rarely used in formal RCT designs — almost all trials used capsule extracts
I am not telling you to take this. Speak to a clinician — particularly if you have any liver condition or are on chronic medication.
Safety — why this section matters more for Shilajit than most herbs
This is where the reader needs the most honesty.
In the formal trials, purified Shilajit was generally well-tolerated. Reported adverse events were mild — GI upset, occasional headache.
But the Indian retail market for Shilajit is characterised by widespread adulteration and heavy-metal contamination concerns. A 2024 review in Biological Trace Element Research (Yousuf et al.) noted that Shilajit naturally contains around 65 mineral elements including lead, arsenic, mercury, cadmium, and aluminium. Properly purified resin chelates many of these into less bioavailable forms; unprocessed or adulterated product does not.
A 2024 ConsumerLab batch test on US-market Shilajit found that, when products were tested at the recommended single dose, levels of lead, cadmium, arsenic, and mercury were below thresholds of concern in most products — but several were not.
What the marketing claims vs what the evidence supports
Walk into any Indian pharmacy or scroll Amazon India for "shilajit benefits for male" and you will see claims that span: testosterone, fertility, energy, stamina, immunity, anti-aging, brain function, weight loss, cardiovascular health, and "cellular rejuvenation."
What the trials actually support: modest testosterone increases in healthy men aged 45–55, improvements in sperm parameters in men with diagnosed oligospermia, and preservation of muscular strength after fatiguing exercise protocols.
That is a much narrower list than what the marketing implies. The other claims are either based on traditional rasayana framing (which is a different register from clinical evidence) or extrapolated from in-vitro and animal models that have not been replicated in humans.
A closer look at fulvic acid — the ingredient on every label
Fulvic acid is the marker compound most Shilajit brands print on their packaging, and it deserves its own paragraph because most consumers do not know what it actually is.
Fulvic acids are a class of small humic substances formed during the breakdown of plant matter over geological timescales. They are not unique to Shilajit — they exist in soil, peat, lignite, and freshwater sediment. The Shilajit-specific fulvic acid fraction is biologically interesting because it is concentrated and embedded in a mineral matrix, which may affect bioavailability.
Most Shilajit research uses fulvic acid percentage as a proxy for product authenticity. A genuine purified resin should test at 15–20% fulvic acid; concentrated powders may go higher. A label that doesn't print a fulvic acid percentage is making a claim of purity it doesn't let you verify.
What fulvic acid does biologically in humans is much less clear than the marketing implies. The mechanistic literature points to antioxidant activity, mineral chelation, and possible immunomodulatory effects — most of it from in-vitro work.
How Shilajit compares to better-evidenced Indian herbs
This is the comparison most marketing avoids, and the one I think readers most need.
A reader who came to this article expecting Shilajit to be at the top of the Ayurvedic evidence stack is going to be surprised. Despite its cultural prominence and search volume, Shilajit's clinical evidence base is one of the smallest among major Indian traditional supplements.
This is not the same as saying Shilajit doesn't work. It is saying we don't yet have the trials to know with confidence what it does and doesn't do.
What I changed my mind about while writing this scorecard
I went into this expecting a Promising verdict — partly because Shilajit's traditional reputation is so strong and partly because I'd read the Pandit testosterone trial and found it reasonable.
What pulled me back to LIMITED was the totality picture. Six trials. Two narrow indications. Heavy industry funding. No replication outside narrow geographic and demographic windows. Heavy-metal contamination and adulteration as documented retail-market problems. The published case literature on Shilajit-related liver injury is smaller than for ashwagandha or giloy, but the broader concern about quality control across the Indian Shilajit supply chain is real.
A reader who buys Shilajit anyway should know they are buying ahead of the formal evidence. That can be a perfectly reasonable choice — traditional indications are not zero — but it should be a choice made with the gap visible.
How marketing built the Shilajit boom
This is the editorial context I think readers deserve. Shilajit was a niche traditional supplement in India until roughly 2015. The category exploded between 2018 and 2024 driven by three forces.
First, the global "tribal wisdom" wellness aesthetic — Western influencers and biohackers discovered Himalayan resin as a natural testosterone booster, drove search volume, and Indian brands followed.
Second, the rise of online health-supplement direct-to-consumer brands in India (Kapiva, Wellbeing Nutrition, Setu, and others) who built marketing infrastructure around premium-positioned Shilajit products.
Third, celebrity and Bollywood endorsements that amplified the testosterone-boosting and energy-enhancing positioning.
What did not grow at the same rate: the published clinical evidence base. Marketing infrastructure scales fast. Trial publication is slower and harder. The gap between the two is the consumer-trust problem this scorecard exists to flag.
What an honest Shilajit brand would tell you
If a Shilajit brand were optimising for evidence-based reader trust, here is what their packaging and website would communicate.
The species and geographical origin of the source material — for example, "Asphaltum punjabianum sourced from Garhwal Himalayas at 4,000+ metres altitude." Not "premium Himalayan."
The purification method, ideally with reference to Shodhana steps performed and any modern processing applied. Not "traditionally purified."
The fulvic acid percentage by HPLC assay, with the assay method named.
A heavy-metal Certificate of Analysis with actual numerical values for lead, arsenic, mercury, and cadmium, batch-matched to the bottle in your hand.
The recommended daily dose, the corresponding fulvic acid milligrams, and any contraindications including pregnancy, liver disease, and concurrent medications.
The manufacturer's contact details and a clear customer service channel for adverse-event reports.
Almost no Shilajit brand on the Indian retail market currently meets all six criteria. The fact that this is the bar, and that we are mostly far from it, is the consumer-protection story for this entire category.
The bottom line
Shilajit's clinical evidence base is one of the smallest among widely-marketed Indian Ayurvedic supplements. Two narrow indications — testosterone in healthy aging men and fatigue resistance in trained males — have replicated trial signals. Almost everything else in the marketing landscape is preclinical or extrapolated. The most concrete consumer issue is purity and heavy-metal contamination in the unregulated end of the Indian retail market, not the herb's inherent pharmacology. I would not pay a price premium for Shilajit on the current evidence, and I would only buy a brand that publishes a heavy-metal Certificate of Analysis.
What an honest Shilajit research agenda would look like
I want to spell this out because most readers won't see it elsewhere. If a research consortium wanted to actually settle the Shilajit evidence question over the next five years, here is what would need to happen.
A multi-centre RCT of standardised purified Shilajit extract at 500 mg/day for 6 months in healthy adults of both genders, with lipid panel, glucose, cortisol, testosterone, and quality-of-life endpoints, conducted outside India to address replication concerns. Sample size n > 300. None of this currently exists in published form.
A head-to-head pharmacokinetic study comparing PrimaVie capsule, generic Indian Shilajit capsule, and Shilajit resin at matched fulvic-acid-equivalent doses, measuring plasma fulvic acid and dibenzo-α-pyrone metabolites over 24 hours. This would resolve the form-bioavailability question that currently drives consumer confusion.
A coordinated heavy-metal surveillance programme across the Indian Shilajit retail market, with batch-level testing and public reporting. The 2024 ConsumerLab US-market data is suggestive but not Indian-market-specific, and Indian consumers deserve their own data.
None of this is likely to happen on a typical research-funding timeline because Shilajit's commercial market is fragmented enough that no single brand has the incentive to fund the field-defining studies that, say, KSM-66 funded for ashwagandha. That is the structural reason Shilajit research lags behind better-evidenced Ayurvedic herbs despite higher consumer demand.
What three years of covering this category have taught me
Shilajit has been the most-asked-about herb in HerbVerdict's reader inbox over the past year, and I want to share three pattern observations.
First, most consumers don't realise how much variability exists between Shilajit products. They assume that "Shilajit" is a category like "vitamin C" — a defined chemical with consistent properties. In practice, two Shilajit products at the same price point can deliver substantially different fulvic acid content, heavy-metal profiles, and bioactive compound concentrations.
Second, the gender skew in Shilajit marketing is extreme. Almost all Shilajit advertising in India targets men, particularly around testosterone and sexual-health framing. Women searching for general energy or wellness benefits often don't find Shilajit content tailored to them — partly because the trial evidence is also male-skewed.
Third, the religious and cultural significance of Shilajit varies regionally. In northern Indian Hindu traditions, Shilajit has stronger classical Ayurvedic positioning. In southern Indian and Tamil traditions, the herb is less culturally central. This affects both consumption patterns and brand-loyalty patterns in ways most national-level marketing flattens.
These are not evidence claims. They are observations about how this category actually operates in the Indian wellness market, and they shape how consumers should read the products they encounter.
Frequently asked questions
What are the proven benefits of Shilajit?
The most replicable signals from PubMed-indexed RCTs are modest testosterone increases in healthy men aged 45–55 (90-day Pandit trial) and preservation of muscular strength after fatiguing exercise (Keller 2019). Other widely-marketed claims do not have comparable trial evidence as of April 2026.
Is Shilajit safe to take daily?
Purified Shilajit was generally well-tolerated in trials at 250–500 mg/day for 8–12 weeks. Long-term daily-use safety beyond 6 months is poorly studied. The bigger consumer concern is heavy-metal contamination in unregulated retail product, not the herb itself.
Does Shilajit really increase testosterone?
One PubMed-indexed RCT (Pandit et al., 2016, n=60) showed significant testosterone increases in healthy men aged 45–55 over 90 days vs placebo. The trial was industry-funded and single-centre. The signal is real but narrow.
Why is the evidence for Shilajit weaker than for Ashwagandha?
Ashwagandha has 22+ RCTs across multiple outcomes; Shilajit has 6. The difference is largely about research investment — Ashwagandha has had branded extract manufacturers (KSM-66, Sensoril) funding multi-trial programmes for over a decade. Shilajit's commercial growth has outpaced its research investment.
What form of Shilajit is best?
Most clinical trials used standardised purified extract in capsule form, not raw resin. Resin is closer to traditional preparation but is also the form most likely to be adulterated. We cover the form question in detail in our companion guide on Shilajit gummies vs capsules vs resin.
References
- Pandit S, Biswas S, Jana U, et al. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia. 2016;48(5):570–575. PubMed 26395129
- Biswas TK et al. Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia. 2010. PubMed 19696985
- Keller JL et al. The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength. J Int Soc Sports Nutr. 2019. PubMed 30728074
- Yousuf MA et al. Hazardous or Advantageous: Uncovering the Roles of Heavy Metals and Humic Substances in Shilajit. Biol Trace Elem Res. 2024. PubMed 38393486
- Carrasco-Gallardo C et al. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012. PMC 3296184
- ConsumerLab. Shilajit Supplements Tested for Fulvic Acid and Heavy Metals. 2024. consumerlab.com